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Abstract 
 
Background: Proinflammatory cytokines have been known to be elevated in patients 
with Chronic Heart Failure (CHF). Given the importance of proinflammatory cyto-
kines in the context of the failing heart, the prevalence of Tumor Necrosis Factor-α 
(TNF-α), Interleukin (IL)-6 polymorphisms in patients with CHF was studied due to is-
chemic heart disease. 
 
Methods: Forty three patients with ischemic heart failure were enrolled in this study 
and compared with 140 healthy individuals. The allele and genotype frequency of 
four Single Nucleotide Polymorphisms (SNPs) within the IL-6 (-174, nt565) and TNF-α 
(-308, -238) genes were determined, using Polymerase Chain Reaction with Se-
quence-Specific Primers (PCR-SSP) assay. 
 
Results: The frequency of the TNF-α (-238) A/A genotype was significantly higher in 
patients comparing to controls (p=0.043), while TNF-α G/A genotype at the same po-
sition decreased significantly, in comparison with controls (p=0.018). The most frequent 
haplotype for TNF-α was A/A in the patient group in comparison with controls 
(p=0.003). There was no significant difference in allele and genotype frequencies of 
IL-6 at positions -174 and nt565, and TNF-α at position -308. 
 
Conclusion: Certain alleles, genotypes, and haplotypes in TNF-α, but not IL-6, gene 
were overrepresented in patients with ischemic heart failure, which may, in turn, pre-
dispose individuals to this disease. 
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Introduction 
 
Chronic Heart Failure (CHF) is among the leading 
causes of mortality worldwide, with an incidence rate 
of 10 per 1000 population after the age of 65 1,2. Given  
 
 
 
 
 
the increasing incidence of the disease, identifying 
groups of patients who may be genetically more sus-
ceptible to developing CHF would be essential. Thus 
* Corresponding author: 
Nima Rezaei, M.D., Ph.D.,  
Children’s Medical Center,  
Tehran, Iran 
Tel: +98 21 66576573 
Fax: +98 21 66929235 
E-mail:   
rezaei_nima@yahoo.com 
Received: 30 Jan 2017 
Accepted: 8 May 2017 
 
Avicenna J Med Biotech 2018; 10(2): 105-109 
10
Association of TNF and IL-6 Gene Polymorphisms with Heart Failure 
Avicenna Journal of Medical Biotechnology, Vol. 10, No. 2, April-June 2018     106 
initiating therapy at an early stage of the disease could 
be considered. 
Increased levels of proinflammatory cytokines, in-
cluding Tumor Necrosis Factor-α (TNF-α) and Inter-
leukin (IL)-6, have been previously reported in patients 
with CHF 3-6. Meanwhile, their roles in the develop-
ment and progression of the underlying Ischemic Heart 
Disease (IHD) are also well established 7,8. Genetic 
polymorphisms within the coding and promoter regions 
of proinflammatory cytokine genes have been de-
scribed to regulate gene expression, ultimately altering 
cytokine production 9-11. The association between some 
cytokine gene polymorphisms and a number of diseas-
es has been previously studied 12-17. Indeed association 
of TNF-α with the susceptibility to and severity of 
CHF has also been examined. The promoter region of 
TNF-α gene contains several SNPs which influence 
gene expression or cytokine secretion. In addition to 
genetic variations, environmental stimuli of inflamma-
tory processes, such as smoking and obesity, were 
shown to influence TNF-α protein concentrations, fur-
ther contributing to individualized differences in TNF-
α level 18,19. The overall contribution of genetic varia-
tion to the development of CHF is not well established. 
TNF-α -308G/A polymorphism is one of the widely 
studied polymorphisms in CHF; however, despite their 
association with other inflammatory diseases, a com-
prehensive review of the literatures fails to show any 
relationship between TNF-α polymorphism and the 
presence of CHF or the elevation of circulating TNF-α 
20. However, the role of polymorphisms in other pro-
inflammatory cytokine genes in CHF has not been fully 
investigated. 
The objective of this research was to study proin-
flammatory cytokine gene polymorphisms in Iranian 
patients with CHF due to IHD. 
 
Materials and Methods 
 
Subjects: In the present study, a total of 43 consecu-
tive Iranian patients with chronic ischemic heart failure 
(mean age 60.05±11.97 yr; 34 men, 9 women) with 
angiographically significant Coronary Artery Disease 
(CAD), defined as ≥50% diameter stenosis in at least 
one of the major coronary arteries, were enrolled. The 
diagnosis of CHF was based on impaired left ventricu-
lar systolic function (left ventricular ejection fraction 
≤40%) and left ventricular dilation (left ventricular 
end-diastolic diameter >5.5 cm) on echocardiography. 
All patients underwent transthoracic echocardiography 
and cardiac catheterization. Subjects with chronic lung 
disease, malignancies, recent myocardial infarction, 
and acute decompensated heart failure within 3 months 
before recruitment were excluded. Eligible patients 
were in stable clinical condition and received conven-
tional medical therapy for at least 3 months.  
One hundred and forty healthy control subjects were 
randomly selected from blood donors at Iranian blood 
transfusion organizations, as previously described 21. 
Written informed consent was obtained from all partic-
ipants prior to blood sampling. This study was ap-
proved by the Ethical Committee of Tehran University 
of Medical Sciences. 
 
Genotyping 
Genomic DNA was isolated from peripheral blood 
leukocytes, using salting-out method. Cytokine typing 
was performed by polymerase chain reaction with se-
quence-specific primers (PCR-SSP) assay (PCR-SSP 
kit, Heidelberg University, Heidelberg, Germany), as 
previously described in details 21. Briefly, amplification 
was carried out using a thermal cycler Techne Flexi-
gene apparatus (Rosche, Cambridge, UK). The pres-
ence or absence of PCR products was visualized by 2% 
agarose gel electrophoresis. All individuals were geno-
typed for polymorphic sites of the following cytokine 
genes: IL-6, -174 G/C and nt565 G/A; TNF-α, -308 
G/A and -238 G/A. 
 
Statistical analysis 
Statistical analyses were performed with EPI info 
software. Allele, genotype, and haplotype frequencies 
for all cytokine gene polymorphisms were calculated 
by direct counting. Frequencies of alleles, genotypes, 
and haplotypes were compared between the patient and 
control groups using the Fisher’s exact test. The odds 
ratio with 95% confidence intervals was calculated. 
 
Results  
 
Alleles and genotype frequencies 
Allelic and genotype frequencies in patients with is-
chemic heart failure and healthy controls are presented 
in table 1. It should be noted that among 140 controls 
enrolled in the original study 21, results of three con-
trols were not conclusive for TNF-α, while no result 
was detected for IL-6 of a control. 
A significant positive association with the A/A gen-
otype was found for TNF-α at position -238 in our pa-
tients compared to controls (7 vs. 0.7%, p=0.043), 
while TNF-α G/A genotype at the same position de-
creased significantly in patients compared to controls 
(20.9 vs. 41.6%, p=0.018). 
The allele and genotype frequencies of IL-6 at posi-
tions -174 and nt565, and TNF-α at position -308 were 
similar in two groups of patients and controls. 
 
Haplotype frequencies 
Haplotype frequencies in patients with ischemic 
heart failure and healthy control subjects are shown in 
table 2. The most frequent haplotype for TNF-α (posi-
tions -308, -238) was A/A in the patient group in com-
parison with controls (4.7 vs. 0%,  p=0.003). 
 
Discussion 
 
There is a paucity of data in the literature on the as-
sociation of TNF-α -238G/A polymorphism with CHF. 
Bruggink et al reported increased frequency of TNF-α -
238/A allele in patients suffering from dilated cardio-
myopathy on left ventricular assisted device compared 
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to patients on medical therapy 22. However, no such as-
sociation was reported in patients with ischemic heart 
failure 22. In the present study, the TNF-α (-238) A/A 
genotype frequency in patients with ischemic heart fai-
lure was significantly higher, while the G/A genotype 
at the same position was significantly lower than con-
trols. Moreover, the frequency of TNF-α (-308, -238) 
A/A haplotype was higher in patients compared to con-
trols. To the best of our knowledge, this is the first re-
port describing an association between TNF-α (-238) 
A/A genotype and TNF-α (-308, -238) A/A haplotype 
with ischemic heart failure. The number of patients 
with this haplotype was low; however, it should be 
emphasized that a very rare haplotype was found that 
was more common among patients with ischemic heart 
failure than healthy controls. Although this might be a 
chance finding, the results need to be replicated in oth-
er, preferably larger, population with greater haplotype 
diversity. Moreover, given the small number of pa-
tients in this study, any conclusions can only be inter-
preted with caution.  
There are conflicting reports on the influence of 
TNF-α -238G/A polymorphism on the expression level 
of TNF-α. The TNF-α -238/A allele has been reported 
to be associated with both increased and decreased 
TNF-α expression 9,23, whilst other investigators report-
ed no significant association between TNF-α -238G/A 
polymorphism and the cytokine expression level 24,25. 
A single SNP, together with other SNPs, may only be 
able to modify the disease phenotype in an appropriate 
environmental context. Therefore, circulating TNF-α 
levels might reflect combined effects of multiple SNPs, 
in addition to environmental factors. This might in part 
explain the conflicting reports regarding the influence 
of TNF-α -238G/A polymorphism on the expression 
level of TNF-α. 
Increased levels of IL-6 have been described repeat-
edly in patients with CHF with a positive correlation 
with disease severity. Previous studies have also re-
ported the association between the polymorphisms in 
the promoter region of the IL-6 gene and altered cyto-
kine production 10,26. However, to the best of our 
knowledge, the association between IL-6 gene poly-
morphisms and risk of ischemic heart failure has not 
been reported previously. In the present study, no asso-
ciation between -174G/C and +565A/G polymorphisms 
in the IL-6 gene and ischemic heart failure was found.  
Relationship between polymorphisms in the TNF-α 
 
Table 1. Comparisons of allele and genotype frequencies between patients with ischemic heart failure and controls 
 
Cytokine Position Alleles/Genotypes Patients (n=43)  N (%) 
Controls (n=140) 
N (%) p-value Odds ratio (95% CI) 
TNF-α 
 -308 
A 
G 
AA 
GA 
GG 
14 (16.3) 
72 (83.7) 
1 (2.3) 
12 (27.9) 
30 (69.8) 
39 (14.2) 
235 (85.8) 
0 (0) 
39 (28.5) 
98 (71.5) 
0.606 
0.606 
0.239 
1.000 
0.848 
1.17 (0.60 to 2.28) 
0.85 (0.44 to 1.66) 
9.71 (0.39 to 242.9) 
0.97 (0.45 to 2.09) 
0.92 (0.43 to 1.94) 
 -238 
A 
G 
AA 
GA 
GG 
15 (17.4) 
71 (82.6) 
3 (7) 
9 (20.9) 
31 (72.1) 
59 (21.5) 
215 (78.5) 
1 (0.7) 
57 (41.6) 
79 (57.7) 
0.449 
0.449 
0.043* 
0.018* 
0.108 
0.77 (0.41 to 1.44) 
1.30 (0.69 to 2.43) 
10.20 (1.03 to 100.8) 
0.37 (0.17 to 0.83) 
1.90 (0.90 to 4.01) 
IL-6 
 
-174 
C 
G 
CC 
GC 
GG 
26 (30.2) 
60 (69.8) 
2 (4.6) 
22 (51.2) 
19 (44.2) 
101 (36.3) 
177 (63.7) 
4 (2.9) 
93 (66.9) 
42 (30.2) 
0.365 
0.365 
0.628 
0.072 
0.099 
0.76 (0.45 to 1.28) 
1.32 (0.78 to 2.22) 
1.65 (0.29 to 9.32) 
0.52 (0.26 to 1.04) 
1.83 (0.91 to 3.69) 
 
+565 
A 
G 
AA 
GA 
GG 
16 (18.6) 
70 (81.4) 
0 (0) 
16 (37.2) 
27 (62.8) 
50 (18) 
228 (82) 
4 (2.9) 
42 (30.2) 
93 (66.9) 
0.874 
0.874 
0.574 
0.455 
0.713 
1.04 (0.56 to 1.944) 
0.96 (0.51 to 1.79) 
0.35 (0.018 to 6.56) 
1.37 (0.67 to 2.80) 
0.835 (0.41 to 1.70) 
 
Table 2. Comparisons of haplotype frequencies of TNF-α and IL-6 between patients with ischemic heart failure and controls 
 
Cytokine Haplotype Patients  (n=43) N (%) 
Controls (n=140) 
N (%) Odds ratio (95% CI) p-value 
TNF-α (-308, -238) 
GG 61 (70.9) 176 (64.2) 1.36 (0.80 to 2.30) 0.298 
AG 10 (11.6) 39 (14.2) 0.79 (0.38 to 1.66) 0.594 
GA 11 (12.8) 59 (21.5) 0.53 (0.27 to 1.07) 0.086 
AA 4 (4.7) 0 (0) 29.95 (1.6 to 562.4) 0.003* 
IL-6 (-174, nt565) 
GG 57 (66.3) 173 (62.2) 1.19 (0.72 to 1.98) 0.525 
CG 13 (15.1) 55 (19.8) 0.72 (0.37 to 1.4) 0.429 
CA 13 (15.1) 46 (16.6) 0.90 (0.46 to 1.76) 0.868 
GA 3 (3.5) 4 (1.4) 2.51 (0.55 to 11.45) 0.361 
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and IL-6 genes and IHD, as one of the most common 
causes of CHF, has been reported but remains contro-
versial. Bennet et al reported no significant association 
between five SNPs in the TNF-α promoter region (-
238G/A, -308G/A, -857C/T, -863C/A, and -1031T/C) 
and risk of Myocardial Infarction (MI) 27. Similarly, 
allele frequencies, and genotype and haplotype distri-
butions of the TNF-α promoter polymorphisms -863C/ 
A and -308G/A were not related to the risk of CAD 
and MI 28. In another study, none of the four TNF-α 
SNPs (-806C/T, -308G/A, -238G/A, and +467G/A) 
investigated reached statistical significance in the total 
sample of patients; however, a significant interaction 
between 238G/A polymorphism and risk of CHD was 
reported among nonsmokers in Chinese Han popula-
tion 29. Regarding the role of IL-6 gene polymorphisms 
in CHD, in a very recent meta-analysis, it was shown 
that the IL-6 -174G/C polymorphism is not significant-
ly associated with increased risk of CHD; however, a 
significant association can be found between the -572- 
G/C polymorphism in the IL-6 gene and CHD risk, 
especially in Asian populations 30.  
While significant differences in some cytokine gene 
polymorphisms were found between the two groups of 
patients and controls, the small sample size can affect 
the robustness of the findings. Moreover, since the role 
of TNF-α and IL-6 SNPs in the pathogenesis of CHD 
has remained inconclusive, investigating patients with 
IHD and no heart failure might have given more con-
clusive results. 
 
Conclusion 
 
In conclusion, this study demonstrates the associa-
tion between certain allele, genotype, and haplotype 
frequencies in TNF-α gene with ischemic heart failure. 
Further investigation, using a larger sample size, to 
obtain more conclusive data regarding the role of TNF-
α genotype in the pathogenesis of ischemic heart fail-
ure and influence on TNF-α level is warranted. 
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